Emerging roles of bile acids in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma

This publication has 15 references indexed in Scilit:

• Ursodesoxycholic acid alleviates liver fibrosis via proregeneration by activation of the ID1‐WNT2/HGF signaling pathway
  Clinical and Translational Medicine, 2021
• Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function
  Cellular & Molecular Immunology, 2021
• Gut microbiome, liver immunology, and liver diseases
  Cellular & Molecular Immunology, 2020
• Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy
  Pharmacology & Therapeutics, 2019
• Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
  Cell, 2019
• Ursodeoxycholic acid accelerates bile acid enterohepatic circulation
  British Journal of Pharmacology, 2019
• EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
  Journal of Hepatology, 2017
• Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis
  Journal of Proteome Research, 2015
• Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism
  Hepatology, 2014
• Bile acids increase hepatitis B virus gene expression and inhibit interferon‐α activity
  The FEBS Journal, 2010